Le Tang

Dr. Le Tang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2024 in Hepatology
Verified
Journal Article
Open access
GFGuangyu Fan
Guangyu Fan
TTTao, Changcheng Tao
Tao, Changcheng Tao
LLLin Li
Lin Li
TXTongji Xie
Tongji Xie
LTLe Tang
Le Tang
YSYuan-kai Shi
Yuan-kai Shi
Intra-tumor immune infiltration is a crucial element interacting with tumor cells in intrahepatic cholangiocarcinoma (ICC). However, its phenotype and related spatial structure remained elusive. To address these limitations, we undertook a comprehensive study combining spatial data (29,632 spots from six samples) and single-cell data (21,158 cells from 35 samples). We identified two distinct infiltration patterns: macrophage+ (characterized by CD68 and MARCO) and plasma cell+ (characterized by IGHG1 and JCHAIN). The macrophage+ and plasma cell+ signatures showed adverse and favorable roles in ICC patients’ survival, respectively. Notably, MARCO+ tumor-associated macrophage (TAM) was recognized as the main cell type in macrophage+ samples, indicating an immune-resistant microenvironment. Increased epithelial-mesenchymal transition activities, angiogenesis, and hypoxia were observed in MARCO+ TAM. The co-location of MARCO+ TAM and CTSE+ tumor cells was observed in spatial transcriptomics and bulk transcriptomics data, validated by multiplex immunofluorescence performed on twenty ICC samples. The co-location area exhibited similar protumorigenic pathways and suppressed immune response. CTSE exhibited associations with intrahepatic metastasis and vascular invasion. Both MARCO+ TAM and CTSE+ tumor cells were associated with worse survival and patients with high infiltration of two cell types displayed the worst survival. Within the co-location area, the galectin signaling pathway was most active in cell-cell communication, with LGALS9-CD44 identified as the main ligand-receptor pair. This study identified macrophage+ and plasma cell+ intra-tumor immune infiltration patterns and the co-location of MARCO+ TAM and CTSE+ tumor cells as contributors to immune resistance. Export

2 December 2019 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
DSDandan Shao
Dandan Shao
JZJia-Yong Zhang
Jia-Yong Zhang
LTLe Tang
Le Tang
QYQiuli Yu
Qiuli Yu
XHXiaoxiao Hu
Xiaoxiao Hu
ZZZigui Zhang
Zigui Zhang

11 December 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
RLRongrong Luo
Rongrong Luo
XLXiying Li
Xiying Li
RGRuyun Gao
Ruyun Gao
MYMengwei Yang
Mengwei Yang
JCJuan Cai
Juan Cai
XHXiaohong Han
Xiaohong Han
Autoantibodies hold promise for diagnosing lung cancer. However, their effectiveness in early-stage detection needs improvement. In this study, we investigated novel IgG and IgM autoantibodies for detecting early-stage lung adenocarcinoma (Early-LUAD) by employing a multi-step approach, including Human Proteome Microarray (HuProtTM) discovery, focused microarray verification, and ELISA validation, on 1246 individuals consisting of 634 patients with Early-LUAD (stage 0–I), 280 patients with benign lung disease (BLD), and 332 normal healthy controls (NHCs). HuProtTM selected 417 IgG/IgM candidates, and focused microarray further verified 55 significantly elevated IgG/IgM autoantibodies targeting 32 tumor-associated antigens in Early-LUAD compared to BLD/NHC/BLD+NHC. A novel panel of 10 autoantibodies (ELAVL4-IgM, GDA-IgM, GIMAP4-IgM, GIMAP4-IgG, MGMT-IgM, UCHL1-IgM, DCTPP1-IgM, KCMF1-IgM, UCHL1-IgG, and WWP2-IgM) demonstrated a sensitivity of 70.5% and a specificity of 77.0% or 80.0% for distinguishing Early-LUAD from BLD or NHC in ELISA validation. Positive predictive values for distinguishing Early-LUAD from BLD with nodules ≤ 8 mm, 9–20 mm, and > 20 mm significantly increased from 47.27%, 52.00%, and 62.90% [low-dose computed tomography (LDCT) alone] to 79.17%, 71.13%, and 87.88% (10-autoantibody panel combined with LDCT), respectively. The combined risk score (CRS), based on the 10-autoantibody panel, sex, and imaging maximum diameter, effectively stratified the risk for Early-LUAD. Individuals with 10 ≤ CRS ≤ 25 and CRS > 25 indicated a higher risk of Early-LUAD compared to the reference (CRS < 10), with adjusted odds ratios of 5.28 [95% confidence interval (CI): 3.18–8.76] and 9.05 (95% CI: 5.40–15.15), respectively. This novel panel of IgG and IgM autoantibodies offers a complementary approach to LDCT in distinguishing Early-LUAD from benign nodules.

21 October 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
LHLiling Huang
Liling Huang
TXTongji Xie
Tongji Xie
FZFuqiang Zhao
Fuqiang Zhao
YFYu Feng
Yu Feng
HZHaohua Zhu
Haohua Zhu
YSYuan-kai Shi
Yuan-kai Shi
Background. It is still an unmet clinical need to identify potent biomarkers for immunotherapy on patients with lung squamous cell carcinoma (LUSC). Methods. In this study, we explored the differentially expressed genes (DEGs) that were simultaneously correlated with four pathways (i.e. CD8+αβT cell proliferation/differentiation/activation pathways and ferroptosis pathway) and possibly related to the remodeling of tumor microenvironment via the TCGA-LUSC dataset. Besides, four GEO datasets (GSE157009, GSE157010, GSE19188, and GSE126045) and IMvigor210 dataset were utilized for confirmation and validation. Results. The co-downregulated DEG DLX2 was selected for further analysis. Function enrichment analysis revealed that low-expression of DLX2 was closely related to various immune-related pathways like T/B/NK cell mediated immunity, interferon gamma/alpha response, and various autoimmune disease. DLX2-downregulated group was enriched in more immune-activating cells and lower tumor immune dysfunction and exclusion (TIDE) score. Via the Cancer Immunome Atlas (TCIA) database, lower expression of DLX2 was also found to be associated with better IPS score of PD-1/PD-L1 blockade ( ) as well as CTLA-4 combined with PD-1/PD-L1 blockade ( ). Furthermore, patients in DLX2-low group were found to have significant longer median OS than those in DLX2-high group in IMvigor210 dataset (10.8 vs 7.4 months; hazard ratio [HR]=0.74, 95% confidence interval [95%CI] 0.57-0.96; ). Conclusions. Our study on an integrated bioinformatical analysis implied that DLX2 could be served as a promising indicator for remodeling tumor microenvironment status and predicting ICI response of patients with LUSC.

24 February 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
YQYuquan Qian
Yuquan Qian
LTLe Tang
Le Tang
JYJiarui Yao
Jiarui Yao
YZYiming Zhu
Yiming Zhu
YZYe Zhang
Ye Zhang
LGLin Gui
Lin Gui
Purpose: Patients with recurrent or metastatic sinonasal squamous cell carcinoma (R/M SNSCC) lack standardized systemic treatment and prospective studies. We evaluated the antitumor response and safety of pembrolizumab with nab-paclitaxel and platinum in R/M SNSCC. Patients and Methods: Patients with R/M SNSCC received pembrolizumab 200 mg and nab-paclitaxel 260 mg/m2 plus cisplatin 75 mg/m2 or carboplatin at an AUC 5 on day 1 every 21 days for up to six cycles, followed by pembrolizumab maintenance until progression or unacceptable toxicity or 35 cycles. The primary endpoint was the objective response rate (ORR). Secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), and safety. IHC and high-resolution sequencing of the tumor samples were performed. Results: The ORR in 20 patients was 60.0% (95% confidence interval, 36.1%–80.9%), and two patients (2/20, 10%) achieved complete response. The disease control rate was 100%. The median follow-up was 18.1 months (range, 5.2–31.7), the median PFS was 12.2 months (95% confidence interval, 9.0 months–not estimated), and the median OS was not reached. Patients with a PD-L1 combined positive score ≥20 exhibited better ORR (80.0% vs. 28.6%, P = 0.144), median PFS (not reached vs. 7.0 months, P = 0.0137), and median OS (not reached vs. 17.8 months, P = 0.0401) compared with those with a PD-L1 combined positive score <20. Grade 3/4 treatment-related adverse events (AE) accounted for 30.0% (6/20) of AEs, and all were hematologic toxicities. Hypothyroidism was the most common immune-related AE (12/20, 60.0%). Conclusions: Pembrolizumab plus nab-paclitaxel and platinum shows promising antitumor activity and manageable safety in patients with first-line R/M SNSCC.

11 December 2024 in Hepatology Communications
Verified
Journal Article
Open access
GFGuangyu Fan
Guangyu Fan
LDLiyuan Dai
Liyuan Dai
TXTongji Xie
Tongji Xie
LLLin Li
Lin Li
LTLe Tang
Le Tang
YSYuan-kai Shi
Yuan-kai Shi
Background: Microvascular invasion (MVI) is a critical prognostic factor in intrahepatic cholangiocarcinoma (ICC), strongly associated with postoperative recurrence. However, the phenotypic features and spatial organization of MVI remain inadequately understood. Methods: We performed a spatial transcriptomic analysis on 29,632 spots from six ICC samples, manually delineating MVI clusters using the cloupe software. Key biomarkers were identified and validated in an independent cohort of 135 ICC patients. Functional and survival analyses were conducted to assess clinical relevance, and cell-cell communication pathways were investigated. Results: MVI regions exhibited heightened proliferation, angiogenesis, and epithelial-mesenchymal transition, driven by increased expression of transcription factors SOX10, ZEB1, and SNAI2. CXCL5 and SLC6A14 were identified as potential MVI biomarkers and showed high expression in tumor-invasive areas. Serum CXCL5 demonstrated strong predictive power for vascular invasion (AUC = 0.92) and intrahepatic metastasis (AUC = 0.96). High expression of both CXCL5 and SLC6A14 was associated with the worst survival outcomes. MVI regions were enriched with immunosuppressive MRC1+ macrophages and exhibited elevated immune checkpoint expression, including HAVCR2 and TIGHT, indicative of immune resistance. Cell-cell communication analysis revealed CXCL5-CXCR2 and LGALS9-HAVCR2 as key ligand-receptor pairs contributing to the immunosuppressive microenvironment. Conclusions: This study identifies CXCL5 and SLC6A14 as key biomarkers of MVI, highlighting their roles in tumor proliferation, immune resistance, and poor clinical outcomes. These findings provide valuable insights into the spatial organization of MVI and its contribution to ICC progression, offering potential therapeutic targets.